Access pharmaceuticals To Host Third Quarter Investor Call on Wednesday, November 28th

Company Schedules Conference Call Wednesday, November 28th at 11:00AM ET to Update Investors on MuGard Commercial Activities

Dallas, TX and New York, NY, November 14, 2012 – ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, will host an investor call to update investors on MuGard commercialization activities, including progress with pharmacy benefit managers, payers and pharmacy formularies, and other new developments within the program.

 

The investor conference call is scheduled to be held on Wednesday, November 28, 2012 at 11:00 am ET.  Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time.

 

A replay of the call will be available starting on November 28, 2012 at 1:00 pm ET, through December 11, 2012 until 11:59 pm ET.  Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and conference ID number 377785.

 

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, and ProLindac™, a second generation DACH platinum drug. The Company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

 

ACCESS PHARMACEUTICALS ANNOUNCES PRIVATE PLACEMENT FINANCING

Company financing includes $4.7 million of new investment and the exchange of approximately $5.3 million of outstanding dividends payable

Use of Proceeds Include Repayment of Outstanding Debt and Working Capital

Dallas, TX and New York, NY, October 25, 2012

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP),an emerging biopharmaceutical company, announced that it has entered into definitive agreements for the purchase of $10.0 million of units, consisting of newly issued Access Series B Convertible Preferred Stock and warrants in a private placement with existing investors. The Series B Convertible Preferred Stock is convertible into common stock at $0.50 per share, and the unit provided for 100% warrant coverage with an exercise price of $0.50 per share and a term of six years.  The financing consists of approximately $4.7 million of new investment and the exchange of approximately $5.3 million of outstanding dividends payable. The transaction is expected to close today, subject to the satisfaction of customary closing conditions.

“We believe this financing strengthens the Company’s financial position by enabling the repayment of overdue debt and significantly reducing the level of outstanding dividends payable,” said Jeffrey Davis, CEO of Access Pharmaceuticals, Inc.  He continued, “This financing gives us the resources to continue MuGard commercialization efforts, and we appreciate the continued support of our current investor group.”

The securities issued in this private placement have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and were issued and sold in a private placement pursuant to Regulation D of the Securities Act.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, and ProLindac™, a second generation DACH platinum drug. The Company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard and Cobalamin, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

 

Access Pharmaceuticals To Host Second Quarter Investor Call on Thursday, August 23, 2012

Company Schedules Conference Call Thursday, August 23rd at 11:00AM ET to Update Investors on MuGard Commercial Activities

Dallas, TX and New York, NY, August 17, 2012

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology and oncology supportive care, will host an investor call to update investors on MuGard commercialization activities, including progress with pharmacy benefit managers, payers and pharmacy formularies, and other new developments within the program.

The investor conference call is scheduled to be held on Thursday, August 23, 2012 at 11:00 am ET.  Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time.

A replay of the call will be available starting on August 23, 2012 at 1:00 pm ET, through September 6, 2012 until 11:59 pm ET.  Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 383 and conference ID number 377785.

About MuGard:

MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.  For more information, please visit www.MuGard.com.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers.

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

 

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

Access Pharmaceuticals Announces Positive Data From MuGard Phase 4 Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium

MuGard Demonstrates Statistically Significant Reduction in Pain Associated With Oral Mucositis, Delay to Onset of Oral Mucositis, and Reductions In Weight Loss and the Use of Opioid Pain Medication

First-in-Kind Trial Design For Medical Device Sets New Standard For Evaluation Of Mucositis Treatment Regimens; Strength of Clinical, Quality of Life And Pharmacoeconomic Data Suggests Use in All Patients at Risk For Mucositis

First Oral Mucositis Treatment Option to Provide Significant Clinical Benefit to Head and Neck Cancer Patients Suffering with Oral Mucositis Side Effect

Dallas, TX and New York, NY, June 28, 2012 

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company developing treatments in areas of oncology and oncology supportive care, announced that Dr. Ron R. Allison of Carolina Radiation Medicine, Greenville, NC, presented results from its ongoing MuGard Phase 4 clinical trial in oral mucositis (OM) at the Multinational Association of Supportive Care in Cancer (MASCC) Conference in New York City. The presentation summarized data from 70 cancer patients undergoing chemoradiation therapy for head and neck cancer. Patients using MuGard experienced a statistically significant reduction in mouth and throat soreness, a statistically significant delay to onset of oral mucositis as measured in days or cumulative radiation, and statistically significant reductions in weight loss during therapy and in the use of opioid pain medication.

“Given the significant oral mucositis typically seen in this head and neck cancer population, the benefits of MuGard shown in the results from this trial are important both clinically and from a patient quality-of-life perspective. It’s critically important that we keep patients as comfortable and nourished as possible during this tough treatment regimen, to optimize clinical outcomes,” stated Dr. Ron R. Allison, a principal investigator in the MuGard trial, Carolina Radiation Medicine, Greenville, NC.  He continued, “MuGard is prescribed to patients at my institute who are not eligible to participate in the clinical trial, and we see less mucositis in those patients compared to other rinses. The MuGard benefits shown, to date, suggest broad application in patients at risk of this debilitating toxicity.”

“The study results are consistent with a conclusion supporting MuGard’s effectiveness in the palliation of oral mucositis. MuGard’s ability to mitigate symptom onset and lessen patient dependence on narcotic analgesics will have important consequences on individuals’ ability to more easily tolerate anti-cancer therapy” stated expert on cancer treatment-related mucosal toxicities, Dr. Stephen Sonis, Clinical Professor in Oral Medicine at Harvard and consultant to Clinical Assistance Programs for this trial.

Key points from the MASCC presentation include:

  • Trial design and populations:  Head and neck cancer patients whose treatment plan calls for receiving up to a maximum cumulative radiation dose of 72 Gray (Gy) are randomized into the MuGard arm or a control rinse (sham) arm. Data are collected and reported for two populations: the efficacy analysis population (EFF) are patients that stayed on study treatment throughout chemoradiation treatment (approximately seven weeks), and the full analysis set (FAS) are all subjects enrolled and randomized and have at least 1 post-radiotherapy assessment. Data presented today was from the first 70 of a planned 120 patients. The patient populations in each arm were well balanced as to age, gender, ethnicity, and mean Karnofsky score (a measure of functional impairment of patients). The Company believes that the rigorous design of the trial for a medical device is unprecedented and sets a high bar for competing products in the market.
  • Pain:  Patients taking MuGard throughout their treatment regimen had a statistically significant reduction in pain. The pain endpoint is a measure of reduction in mouth and throat soreness (MTS) over the course of cancer therapy as measured with the oral mucositis daily questionnaire (OMDQ), a validated mucositis assessment tool. MuGard patients in the EFF population experienced a statistically significant reduction in MTS pain relative to the control rinse (p=0.041). MuGard patients in the FAS population showed a strong trend in pain reduction relative to the control rinse (p=0.110).
  • Delay to Onset:  This endpoint is the delay in onset of oral mucositis as measured in cumulative dose of radiation (measured in grays). MuGard patients in the EFF and FAS populations both experienced a statistically significant delay to onset of oral mucositis (p=0.020 and p=0.007, respectively). The ability to extend the onset of oral mucositis out in time during treatment is important clinically and from a quality-of-life (QOL) perspective.
  • Time to First Occurrence:  This endpoint is a measurement, in days, to the time of first occurrence of oral mucositis. MuGard patients in the EFF and FAS populations both experienced a statistically significant delay in time to first occurrence (p=0.022 and p=0.009, respectively). This statistically significant delay in first occurrence of OM occurred in both the EFF and FAS populations, which the company believes is both clinically important and beneficial from a QOL perspective.
  • Maintenance of Weight:  The study also measured changes in patient weight, in kilograms, at various periods during the study. MuGard patients in the EFF population experienced a statistically significant reduction in weight loss (p=0.036) between their start and completion of radiation treatment. Mean weight loss was 9.1 kg (~20.0 lbs) and 5.2 kg (~11.4lbs) for the control and the MuGard arms, respectively. A reduction in weight loss suggests that patients on MuGard were able to keep themselves better nourished during chemoradiation, which presumably enables them to better tolerate this rather challenging treatment regimen.

Jeffrey B. Davis, President and CEO of Access Pharmaceuticals, commented, “Access believes this MuGard data is ground breaking and unique from at least two perspectives. First, this is the first product that has ever shown a statistically significant positive clinical benefit in managing the pain symptoms and delaying the onset of oral mucositis in the very difficult to treat head and neck cancer population. Second, the rigorous design of the MuGard trial is the first of its kind in a medical device treatment option for oral mucositis, setting a new standard in this area. The clinical and quality-of-life benefits shown in this data echoes what we hear in the marketplace and that is evidenced in the increasing commercial adoption of MuGard.”

 

About the Study:  Access initiated the Phase 4 clinical trial of MuGard in 2010 with first sites opened and subjects enrolled in the first quarter of 2011. The rigorously designed trial is a prospective, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy of MuGard in controlling symptoms caused by oral mucositis in subjects receiving chemoradiation therapy for the treatment of cancers of the head and neck. The protocol, whose primary contributor was Stephen T. Sonis, DMD, DMSc, a thought leader in oral mucositis, is designed to evaluate MuGard with a rigor that is typically associated with drugs or biological. Access believes this trial design is the first to be used to evaluate a device for an oral mucositis indication and distinguishes Access and MuGard from competing companies and products. In addition to the primary study endpoints which assess MuGard’s efficacy, the protocol provides for the collection of a range of other endpoints including quality of life and pharmacoeconomic outcomes. Details on the MuGard Phase 4 clinical trial are available at the ClinicalTrials.gov website (http://clinicaltrials.gov/ct2/show/NCT01283906).

About Oral Mucositis: Oral mucositis (“OM”) is a debilitating side effect of some radiation and chemotherapy cancer treatments, characterized by sores and ulcers in the mouth and throat that make swallowing and continued cancer therapy difficult or impossible. It is estimated that 97% of patients receiving radiation for head and neck cancer, 70% of patients receiving stem cell transplantation and up to 40% of patients receiving conventional chemotherapy develop oral mucositis. The NIH estimates that there are 400,000 patients diagnosed with OM in the US annually, but OM is often under-diagnosed and the population at risk is significantly higher. Oral mucositis can lead to pain and the need for strong pain medication, difficulty or the inability to talk, swallow, eat and drink, weight loss, infection, and in the most severe instances the interruption or stoppage of cancer treatment.

 

About MASCC: MASCC, or the Multinational Association of Supportive Care in Cancer, is the leading international organization dedicated to the research and education in all aspects of supportive care for patients with cancer.  It joined forces with the International Society of Oral Oncology (ISOO) in 1998, and its members represent over sixty countries. The MASCC/ISOO membership includes oncology medical, surgical, and radiology physicians, nurses, dentists, dental hygienists, pharmacists and representatives from industry and non-profit sectors. Symposia are convened annually to share the most recent research in supportive care from throughout the world.

About MuGard: MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.  For more information, please visit www.MuGard.com.

About Access: Access Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for MuGard and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

 

ACCESS PHARMA TO REPORT NEW MUGARD CLINICAL TRIAL DATA THIS WEEK AT THE MASCC/ISOO SYMPOSIUM IN NEW YORK CITY

Podium and Poster Presentations To Be Given On Interim Data From MuGard Phase IV Trial

Dallas, TX and New York, NY, June 26, 2012 – ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, today announced that the results of a recent interim analysis of data from an ongoing MuGard clinical trial will be presented at a joint international symposium of the Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO) on Supportive Care in Cancer.  A podium presentation will be made by one of the lead investigators in the study on Thursday June 28th, and results will be presented in a poster displayed on Friday June 29th. In addition to these presentations, Access will have its MuGard booth in the commercial exhibit hall to educate the attendees on the clinical benefit MuGard offers patients undergoing cancer treatment.  The annual MASCC/ISOO Symposium is the preeminent international conference to focus on supportive care in oncology and will be held this week at the Hilton New York Hotel on Thursday, June 28th – Saturday, June 30th.

About MuGard:

MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments, characterized by inflammation and erythema or ulcerations throughout the oral mucosa.  For more information, please visit www.MuGard.com.

About MASCC:

The Multinational Association of Supportive Care in Cancer (MASCC) is the leading international organization dedicated to the research and education in all aspects of supportive care for patients with cancer.  It joined forces with the International Society of Oral Oncology (ISOO) in 1998, and its members represent over sixty countries. The MASCC/ISOO membership includes oncology medical, surgical, and radiology physicians, nurses, dentists, dental hygienists, pharmacists and representatives from industry and non-profit sectors. Symposia are convened annually to share the most recent research in supportive care from throughout the world.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

 

 

Access Pharmaceuticals MuGard on Formulary at Memorial Sloan-Kettering Cancer Center

Investor Conference Call Today at 11AM ET

DALLAS and NEW YORK, April 4, 2012

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP.OB), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that Memorial Sloan-Kettering Cancer Center (MSKCC) has added MuGard to its cancer supportive care pharmacy formulary.  Patients undergoing cancer treatment will now have direct access to MuGard from the first day of cancer treatment to manage oral mucositis, characterized by inflammation and erythema or ulcerations throughout the oral mucosa.

 

“Having a world-renowned institution like Memorial Sloan-Kettering add MuGard to its formulary is a monumental step in our mission to increase MuGard access for cancer patients,” said Frank Jacobucci, Vice President Sales and Marketing, Access Pharmaceuticals, Inc.  He continued, “Dedicated to the progressive control and cure of cancer, MSKCC is considered one of the best cancer treatment institutions in the world and we are pleased that it has taken action, after their evaluation of MuGard, to treat and potentially eliminate oral mucositis, a debilitating side effect that is often times detrimental to anticancer treatments and lessens the quality of life for cancer patients.

As one of the world’s premier cancer centers, Memorial Sloan-Kettering Cancer Center is committed to exceptional patient care, leading-edge research, and superb educational programs.  Recognized around the world for excellence, Memorial Sloan-Kettering Cancer Center is consistently ranked as one of the nation’s top two cancer centers by U.S. News & World Report. It is designated by the National Cancer Institute as a Comprehensive Cancer Center and is a member of the National Comprehensive Cancer Network.

Conference Call details:

The investor conference will be held today at 11:00 am ET.  Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time.

A replay of the call will be available starting on April 4, 2012 at 1:00 pm ET, through April 18, 2012 until 11:59 pm ET.  Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 383 and conference ID number 377785.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

Access Pharmaceuticals Cowen 32nd Annual Health Care Conference Webcast Link

To view the webcast presentation, click on the following link, http://wsw.com/webcast/cowen6/accp/.

The above webcast will be archived for 90 days after the presentation date.

Access Pharmaceuticals Announces Preliminary Fourth Quarter Revenue Results; MuGard Product Revenue Increases 400% Quarter Over Quarter

DALLAS and NEW YORK, March 5, 2012

Company Cowen Health Care Conference Presentation this Week to Include Update on Commercial Achievements and Review of Preliminary Quarter Results
Company’s Webcast Presentation, Wednesday, March 7th at 8:00am EDT

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP.OB), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology and cancer supportive care,announced preliminary revenue results for fourth quarter 2011 and full year 2011. Fourth quarter MuGard product sales increased 400% over third quarter product sales. Full year 2011 revenues, including license revenues, royalties and research agreements, increased 284% over 2010 figures. Access attributes growth in revenues to increased adoption of MuGard, as well as significant expansion by pharmacy benefit managers and payers to include MuGard in their benefit plans for reimbursement.

Wednesday morning, the Company will present at the Cowen and Company 32nd Annual Health Care Conference, at The Boston Marriott Copley Place in Boston, MA. Mr. Jeffrey Davis, Chief Executive Officer of Access Pharmaceuticals, will give a presentation updating investors on recent commercial advancements within its lead program for oral mucositis, MuGard, and other product programs.

A live webcast of the audio presentation and company slide deck can be accessed via the following link during the presentation time: http://wsw.com/webcast/cowen6/accp/.

About MuGard:

MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments, characterized by inflammation and erythema or ulcerations throughout the oral mucosa. For more information, please visit www.MuGard.com.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

Access Pharmaceuticals Receives Final Marketing Approval From SFDA of China for MuGard

DALLAS and NEW YORK, Feb. 24, 2012

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP.OBNews), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, Rhei Pharmaceuticals HK Ltd., received regulatory and marketing approval for MuGard in China from the State Food and Drug Administration, or SFDA, to treat oral mucositis in cancer patients.  Manufacturing of MuGard will commence shortly in the United States to meet the demand created by Jian An, Rhei’s sales and marketing partner in China.

Last year, Access and RHEI signed a $30 million supply agreement for MuGard to ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.  In addition, Access also approved a sub-license agreement between RHEI Pharmaceuticals and Jian An Pharmaceuticals (“Jian An”) Limited in Shenzhen, China to leverage Jian An’s extensive sales, marketing and regulatory infrastructure for the launch of MuGard in China and Taiwan. Jian An is headquartered in Shenzhen, China and has a 25-year history of selling pharmaceutical and other medical products in the China market.  Jian An has 1400 sales representatives covering all majors centers in China through 169 sales offices.

Expressing enthusiasm on the approval, Jeffrey B. Davis, President and Chief Executive Officer of Access Pharmaceuticals, Inc. stated, “Receiving final marketing approval from the SFDA of China is a transformative milestone for our global MuGard program.  China represents a key target market with its large and increasingly affluent population and its desire for improved oncology care.  With the approval process now complete, we look forward to moving as quickly as we can to complete manufacturing so Rhei and Jian An can launch MuGard through their well established sales and marketing infrastructure in China.”

“China is one of the fastest growing oncology markets and cancer supportive care has been improving throughout recent years,” said Sven De Backer, Chief Executive Officer, Rhei Pharmaceuticals HK Ltd..  He continued, “Rhei and Jian An are proud to bring MuGard to patients and physicians as we believe it is a critical and valuable product that addresses a significant unmet need for a large and growing patient population.”

About MuGard:
MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments, characterized by inflammation and erythema or ulcerations throughout the oral mucosa.  For more information, please visit www.MuGard.com.

About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

About RHEI Pharmaceuticals:
Rhei Pharmaceuticals HK Ltd. (RHEI) is a global pharmaceutical business development firm, with special focus on bringing core medicines from the U.S., Europe and Japan into the fast-growing South-East Asian marketplace. They are experts in business development, regulatory approval and clinical development and have a management team that combines a Western approach to pharmaceuticals with a long experience in Europe, North America and South-East Asia. They use their development capabilities and network of preferred commercial partners to help other pharmaceutical companies introduce their products into specific niche markets, such as the European institutional health care market and the Chinese hospital market. RHEI is headquartered in Hong Kong and has operations in Europe, the USA and China. www.rheipharma.com

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

Access Pharmaceuticals MuGard Added To Nationally Ranked Children’s Hospital Of Colorado Pharmacy Formulary

Dallas, TX and New York, NY, February 16, 2012

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that Children’s Hospital of Colorado has added MuGard to its hospital pharmacy formulary. Children and young adults undergoing cancer treatment will now have direct access to MuGard from the first day of cancer treatment to manage oral mucositis, characterized by inflammation and erythema or ulcerations throughout the oral mucosa.

Commenting on the significance of the event, Frank Jacobucci, Vice President Sales and Marketing, Access Pharmaceuticals, Inc. said, “Having Children’s Hospital of Colorado evaluate MuGard and determine that it has tremendous benefit for their patients undergoing cancer therapy is an important milestone for Access. There are roughly 5800 hospitals in the US with approximately 37 million admissions annually. The hospital inpatient market is very large and currently there is no meaningful intervention for these patients to prevent or treat oral mucositis. The inclusion of MuGard on Children’s Hospital formulary will allow providers and patients to have access to MuGard and potentially eliminate oral mucositis as a side effect of anticancer treatment regimens.”

Top ranked consecutively on the U.S. News & World Report Best Children’s Hospital’s honor rankings since inception, Children’s Hospital Colorado garners local, regional, national and international respect for its treatment and care of children, adolescents and young adults with cancer and non-malignant blood diseases, such as hemophilia and sickle cell anemia. The Center is the only dedicated pediatric cancer center in the Rocky Mountain region, and it is home to numerous specialized programs, which provide state-of-the-art methods for diagnosing and treating complex diseases.

Jeffrey Davis, President and CEO, Access Pharmaceuticals, Inc. stated, “We are thankful that the Children’s Hospital of Colorado recognized the need for a safe, effective and easy-to-use product like MuGard to provide its patients. Affirmations from leading institutions like the Children’s Hospital of Colorado continue to strengthen our belief in MuGard’s clinical benefit and market potential.”

About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.